Stefan Norin named Chief Medical Officer at Oncopeptides

September 1, 2023

Oncopeptides today announces that Stefan Norin has been promoted to new Chief Medical Officer (CMO) at Oncopeptides, effective immediately.

Stefan joined Oncopeptides in March 2019, as Clinical Study Physician, appointed Global Clinical Lead in 2020, Head of Clinical Development in 2022 and Head of Clinical Science in 2023.

Stefan is an MD, specialist in Hematology and Internal Medicine and has a PhD from Karolinska Institute.

Stefan will become part of the Oncopeptides leadership team and his areas of responsibility include pharmacovigilance and patient safety, clinical and preclinical pharmacology and research and development. He replaces Klaas Bakker who left the company earlier this year to take on a new position outside of the company.

“We are excited to see Stefan Norin take on his new and expanded role within the company. With his robust clinical experience in hematology, in depth scientific understanding of Hematological malignancies and given he has been with the company several years Stefan is uniquely positioned to further strengthen Oncopeptides as we continue on our journey to become a leading biotech company in the field of difficult-to-threat cancers,” says Sofia Heigis, CEO at Oncopeptides.

Image of Stefan Norin - Chief Medical Officer

Stefan Norin, Chief Medical Officer (CMO)


For more information, please contact:
David Augustsson, Director of Corporate Affairs:
+46 76 2293868.